Reply to paul et al

Clinical Infectious Diseases

Volumn 49, Issue 4, 2009, Pages 641-642

  Nguyen, Thao D ^a,b,c   Williams, Byron ^b   Ocampo, Norela ^c  

^a Department of Pharmacy Services ^*  (United States)

^b White Memorial Medical Center   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; HEMOPOIETIC GROWTH FACTOR; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACUTE LEUKEMIA; AGE; ANTIBIOTIC THERAPY; BONE MARROW TRANSPLANTATION; BRAIN DISEASE; DEMOGRAPHY; DRUG EFFICACY; DRUG SAFETY; EPILEPTIC STATE; FEBRILE NEUTROPENIA; HEMATOLOGIC MALIGNANCY; HUMAN; LETTER; MONOTHERAPY; MORTALITY; NEUROTOXICITY; NEUTROPHIL COUNT; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 67651086979     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/603588     Document Type: Letter

References (14)

1. Paul M, Yahav D, Fraser A, Leibovici L. Cefepime and all-cause mortality. Clin Infect Dis 2009; 49:640-1 (in this issue).
2. Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:338-48.
3. Chow KM, Hui AC, Szeto CC. Neurotoxicity induced by β-lactam antibiotics: from bench to bedside. Eur J Clin Microbiol Infect Dis 2005; 24:649-53.
4. Sanz MA, Lopez J, Lahuerta JJ, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002; 50:79-88.
5. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, open-label, multicenter comparative study of the efficacy and safety of piperacillin- tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006; 43:447-59.
6. Biron P, Fuhrmann C, Cure H, et al.; CEMIC (Study Group of Infectious Diseases in Cancer). Cefepime versus imipenem-cilastatin as empirical monotherapy in 400 febrile patiens with short duration neutropenia. J Antimicrob Chemother 1998; 42:511-8.
7. Gomez L, Estrada C, Gomez I, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin in the treatment ofpatients with fever and granulocytopenia [abstract L-771]. In: Program and abstracts of the 41st Inter- sciene Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 2001.
8. Bohme A, Shah PM, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study. Eur J Med Res 1998; 3:324-30.
9. Chandrasekar PH, Arnow PM. Cefepime versus ceftazidime as emiric therapy for fever in enutropenic patients with cancer. Ann Pharmacother 2000; 34:989-95.
10. Tamura K, Matsuoka H, Tuskada J, et al.; Kyushu Hematology Organization for Treatment (K-HOT) Study Group. Cefepime or carbapenem tretment for febrile neutropenia as a single agent is a as effective as a combination of 4th-generation cephalosporin + amino- glycosides: comparitive study. Am J Hematol 2002; 71:248-55.
11. Francisca M, Maganti R. Cephalosporin-induced neurotoxicity: clinical manifestations, potential pathogenic mechanisms, and the role of electroencephalographic monitoring. Ann Pharmacother 2008; 42:1843-50.
12. Schliamser SE, Cars O, Norrby SR. Neurotoxicity of ß-lactam antibiotics: predisposing factors and pathogenesis. J Antimicrob Chemother 1991; 27:405-25.
13. Leo RJ, Ballow CH. Seizure activity associated with imipenem use: clinical case reports and review of the literature. DICP 1991; 25:351-4.
14. Machtay M, Kaiser LR, Glatstein E. Is meta- analysis really metaphysics? Chest 1999; 116: 539-42.